Curasight
Phase 1Curasight is a pioneer in the field of exploiting a novel PET imaging target – the urokinase-type plasminogen activator receptor (uPAR) – for improved prostate cancer diagnose.
Founded
2017
Focus
OncologyDiagnostics
About
Curasight is a pioneer in the field of exploiting a novel PET imaging target – the urokinase-type plasminogen activator receptor (uPAR) – for improved prostate cancer diagnose.
Funding History
2Total raised: $26.5M
Series B$20MNovo HoldingsApr 15, 2022
Series A$6.5MNovo SeedsNov 15, 2020
Company Info
TypePrivate
Founded2017
LocationCopenhagen, Denmark
StagePhase 1
Contact
SIMILAR COMPANIES
MipSalus
Pre-clinical · Copenhagen
FluoGuide
Pre-clinical · Copenhagen
Fuse Vectors
Pre-clinical · Copenhagen
Fida Biosystems
Pre-clinical · Copenhagen
CerCell
Pre-clinical · Copenhagen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile